The FDA's 2026 Peptide Review: What Patients Should Know

In July 2026, the FDA's Pharmacy Compounding Advisory Committee met to review whether several peptides, including BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide (DSIP), should be eligible for compounding by pharmacies.

What the Review Is

The committee advises the FDA on which substances may be used by compounding pharmacies. Its recommendations are not binding. The FDA must still review them and complete a formal rulemaking process with public comment before anything changes.

What the Review Is Not

• It is not FDA approval of any peptide.
• It is not a finding that any peptide is safe or effective.
• It is not final. Regulatory status may change, and patients should check FDA.gov for current information.

Questions About Your Care

If you have questions about peptide therapy, call Alpine Health & Wellness in Kalispell, MT at 406-361-7421 or book a consultation online.

This article is for general information only and is not medical or legal advice. Regulatory details reflect publicly available information as of October 2026 and may change; consult FDA.gov and regulations.gov for current status. Compounded medications are not FDA-approved, and the FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed.